What we can learn about cancer drug development from the COVID-19 approach

As an oncologist, I recognize the arduous path to make a new drug. It is a hard trek that lies between the bench and the patient’s bedside. Ordinarily, it takes five or more years just to get a new drug into the clinic for testing. Similar time is needed for clinical trials. Then comes Food and Drug Administration (FDA) approval, followed by the time it takes for licensing, manufacture, distribution and adoption by physicians. Ordinarily, this means that 12 or more years might pass before the FDA even begins its evaluation of a new drug or regimen. This is before any therapy becomes part of our disease-fighting armamentarium.